Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Exclusion Criteria

• •1. Women who are pregnant and/or lactating.
• •2. Splenectomy procedure performed 4 weeks prior to AKR-501 administration.
• •3. Use of the following drugs or treatments prior to Day 1:
• •* Within 3 months - Rituximab;
• •* Within 2 weeks - Aspirin or Aspirin-containing compounds, Salicylates, Anticoagulants, clopidogrel, ticlopidine, Rh0(D) Immune Globulin (WinRho®), or intravenous immunoglobulin (IVIG).
• •4. Participation in a clinical trial involving any investigational agent within 4 weeks of Day 1.
• •5. Exposure to eltrombopag or AMG -531.
• •6. Significant medical conditions or diseases as determined by the Investigator (e.g., clinically active systemic lupus erythematosus; known or suspected HIV infection; acute hepatitis or clinically active chronic hepatitis; lymphoproliferative disease; congestive heart failure).
• •7. History of cardiovascular disease (e.g., angina, unstable angina, myocardial infraction, coronary artery stent placement, angioplasty, coronary artery bypass grafting).
• •8. History of thromboembolic disease (e.g., transient ischemic attack \[TIA\], stroke \[CVA\], pulmonary embolism \[PE\]).
• •9. History of deep venous thrombosis (DVT).
• •10. History of lupus anticoagulant or anticardiolipin antibody syndrome or positive anti b2 glycoprotein antibody.
• •11. History of any medical condition where systemic anticoagulation was required for more than 6 months.
• •12. Laboratory abnormalities:
• •* Hemoglobin \< 12.5 g/dL for men and \< 11.5 g/dL for women. If anemia is clearly related to ITP, for example excessive blood loss, then that patient may be enrolled without the need for a waiver after discussion with the Sponsor's medical monitor
• •* White blood cell count (WBC) \< lower limit of normal
• •* Absolute neutrophil count (ANC) \< 1000/mm\^3
• •* Prothrombin time (PT) \> 1.25 x upper limit of normal
• •* Partial thromboplastin time (PTT) \> 1.25 x upper limit of normal
• •* Total bilirubin \> 3 x upper normal limit
• •* Alanine transaminase (ALT) \> 3 x upper normal limit
• •* Aspartate transaminase (AST) \> 3 x upper normal limit
• •* Creatinine \> 1.5x upper normal limit
• •* Blood urea nitrogen (BUN) \> 1.5 x upper normal limit
• •* HIV positive
• •* IgM HAV positive, Hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV) positive.
• •13. History of, or current alcohol or drug abuse likely to interfere with ability to comply with protocol.
• •requirements or give informed consent, as determined by the Investigator.
• •14. History of, or current psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent, as determined by the Investigator.
• •15. Currently taking any of the following medications: Rituximab, Aspirin or Aspirin-containing compounds, Salicylates, Anticoagulants, clopidogrel, ticlopidine, Rh0(D) Immune Globulin (WinRho®), or intravenous immunoglobulin (IVIG).